Reply to “Novaferon, treatment in COVID-19 patients”
Fang Zheng(Sun Yat-sen University), Guozhong Gong(Central South University), Chunlin Cai(The First Hospital of Changsha), Peihua Niu(National Institute for Viral Disease Control and Prevention), Yuanlin Xie(The First Hospital of Changsha), Wenjie Tan(Sinopec (China)), Baoying Huang(National Institute for Viral Disease Control and Prevention), Qi Zuo(The First Hospital of Changsha), Xin Tan(The First Hospital of Changsha), Wenlong Wang(University Town of Shenzhen), Fei Ye(Unknown), Zhiguang Zhou(Central South University), Yi Li(Suizhou Central Hospital), Wei Tang(Harbin Medical University), Ning Zhou(Tianjin Centers for Disease Control and Prevention), Yanwen Zhou(Central South University), Jun Xie(Hebei North University), Yongfang Jiang(Central South University), Zhiguo Zhou(The First Hospital of Changsha), Yaxiong Huang(The First Hospital of Changsha), Feng Peng(Sichuan University), Jing Ma(St. Jude Children's Research Hospital), Xinqiang Xiao(Central South University), Yun Xu(Huazhong University of Science and Technology)
Cited by 2
Related Papers
A Novel Coronavirus from Patients with Pneumonia in China, 2019
|New England Journal of Medicine|2020|30.5k
Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding
|The Lancet|2020|12.6k
Prevalence of Diabetes among Men and Women in China
|New England Journal of Medicine|2010|3.1k
The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice
|Nature|2020|1.2k